WCG Wealth Advisors LLC Acquires Shares of 35,883 Astrazeneca Plc $AZN

WCG Wealth Advisors LLC acquired a new stake in Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,883 shares of the company’s stock, valued at approximately $6,297,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Triumph Capital Management purchased a new stake in shares of Astrazeneca in the third quarter valued at about $25,000. Bangor Savings Bank raised its holdings in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Eagle Bay Advisors LLC purchased a new stake in shares of Astrazeneca in the fourth quarter valued at about $30,000. YANKCOM Partnership purchased a new stake in shares of Astrazeneca in the fourth quarter valued at about $31,000. Finally, TFC Financial Management Inc. raised its holdings in shares of Astrazeneca by 3,350.0% in the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after buying an additional 335 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca Trading Down 0.7%

NYSE AZN opened at $176.28 on Thursday. The stock has a market capitalization of $273.39 billion, a P/E ratio of 26.47, a P/E/G ratio of 1.41 and a beta of 0.25. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The firm has a 50-day moving average price of $190.88 and a 200 day moving average price of $184.54. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Equities research analysts expect that Astrazeneca Plc will post 10.26 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on AZN shares. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Monday. Finally, Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.